Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M93,683Revenue $M19,620Net Margin (%)10.5Altman Z-Score4.2
Enterprise Value $M97,486EPS $1.9Operating Margin %15.9Piotroski F-Score3
P/E(ttm)61.7Beneish M-Score-2.6Pre-tax Margin (%)12.6Higher ROA y-yN
Price/Book6.410-y EBITDA Growth Rate %10.8Quick Ratio1.1Cash flow > EarningsY
Price/Sales4.75-y EBITDA Growth Rate %-6.0Current Ratio1.5Lower Leverage y-yN
Price/Free Cash Flow42.7y-y EBITDA Growth Rate %-30.9ROA % (ttm)5.8Higher Current Ratio y-yN
Dividend Yield %2.3PEG--ROE % (ttm)12.8Less Shares Outstanding y-yN
Payout Ratio %103Shares Outstanding M1,110ROIC % (ttm)14.1Gross Margin Increase y-yN

Gurus Latest Trades with LLY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LLYVanguard Health Care Fund 2015-06-30 Add0.08%$70.89 - $86.59
($76.14)
$ 84.5111%Add 1.94%25,375,160
LLYKen Fisher 2015-06-30 Add0.04%$70.89 - $86.59
($76.14)
$ 84.5111%Add 29.29%1,029,030
LLYVanguard Health Care Fund 2015-03-31 Add0.45%$68.41 - $76.36
($71.19)
$ 84.5119%Add 13.24%24,892,160
LLYCharles Brandes 2015-03-31 Reduce-0.06%$68.41 - $76.36
($71.19)
$ 84.5119%Reduce 36.80%107,025
LLYKen Fisher 2015-03-31 Add0.03%$68.41 - $76.36
($71.19)
$ 84.5119%Add 37.46%795,909
LLYHOTCHKIS & WILEY 2015-03-31 Add0.01%$68.41 - $76.36
($71.19)
$ 84.5119%Add 0.70%3,968,039
LLYJoel Greenblatt 2015-03-31 Sold Out -0.0031%$68.41 - $76.36
($71.19)
$ 84.5119%Sold Out0
LLYDodge & Cox 2015-03-31 Reduce$68.41 - $76.36
($71.19)
$ 84.5119%Reduce 7.10%36,234
LLYMario Gabelli 2015-03-31 Reduce$68.41 - $76.36
($71.19)
$ 84.5119%Reduce 1.76%111,800
LLYCharles Brandes 2014-12-31 Reduce-1.85%$61.9 - $72.83
($67.53)
$ 84.5125%Reduce 92.65%169,348
LLYRichard Pzena 2014-12-31 Sold Out -0.15%$61.9 - $72.83
($67.53)
$ 84.5125%Sold Out0
LLYKen Fisher 2014-12-31 Add0.07%$61.9 - $72.83
($67.53)
$ 84.5125%Add 383.26%578,992
LLYCharles Brandes 2014-09-30 Reduce-0.29%$60.35 - $66.59
($63.3)
$ 84.5134%Reduce 14.27%2,303,062
LLYHOTCHKIS & WILEY 2014-09-30 Reduce-0.12%$60.35 - $66.59
($63.3)
$ 84.5134%Reduce 10.92%4,321,666
LLYKen Fisher 2014-09-30 Add0.02%$60.35 - $66.59
($63.3)
$ 84.5134%Add 2742.47%119,810
LLYDavid Dreman 2014-09-30 Reduce-0.02%$60.35 - $66.59
($63.3)
$ 84.5134%Reduce 84.40%900
LLYGeorge Soros 2014-09-30 Sold Out -0.02%$60.35 - $66.59
($63.3)
$ 84.5134%Sold Out0
LLYDodge & Cox 2014-09-30 Add$60.35 - $66.59
($63.3)
$ 84.5134%Add 20.38%42,464
LLYJoel Greenblatt 2014-09-30 Reduce$60.35 - $66.59
($63.3)
$ 84.5134%Reduce 27.37%5,628
LLYHOTCHKIS & WILEY 2014-06-30 Add0.73%$58.21 - $63.1
($59.62)
$ 84.5142%Add 199.70%4,851,480
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LLY is held by these investors:


News about LLY:

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: LLY, PLL, SBUX, VLO Jul 07 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks Jun 11 2015 
Abbvie Inc. Dividend Stock Analysis May 26 2015 
Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 
Eli Lilly Inks Major Deal In China To Develop Oncology Segment Mar 23 2015 
Box Inc. Declares Mixed Bag Q4 Results for 2015 Mar 13 2015 
Primecap Management's Annual Shareholder Letter 2014 Mar 09 2015 

More From Other Websites
Insulin Market in Europe – Technavio Analyses Trends & Forecast Jul 31 2015
Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success Jul 31 2015
LILLY ELI & CO Files SEC form 10-Q, Quarterly Report Jul 30 2015
Eli Lilly & Co. Earnings Analysis: By the Numbers Jul 29 2015
Be careful not to raise false hopes over Alzheimer's Jul 28 2015
Market Response to Biogen’s and Eli Lilly’s Alzheimer’s Drugs Jul 28 2015
Why Pharmaceutical Eli Lilly & Co. Warrants Attention from Investors Right Now - Stocks in the News Jul 28 2015
Eli Lilly’s Solanezumab: A Possible Cure for Alzheimer’s? Jul 28 2015
Cramer's shopping list for a pullback Jul 27 2015
Teva to Buy Allergan Generics for $40.5 Billion Jul 27 2015
Lilly continues test of HDL cholesterol drug, on panel's advice Jul 27 2015
Lilly Provides Update on Evacetrapib Phase 3 Trial Jul 27 2015
Lilly Provides Update on Evacetrapib Phase 3 Trial Jul 27 2015
AbbVie: Beware the Biosimilars? Jul 24 2015
3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates Jul 23 2015
Lilly (Eli) (LLY) Earnings Report: Q2 2015 Conference Call Transcript Jul 23 2015
Edited Transcript of LLY earnings conference call or presentation 23-Jul-15 1:00pm GMT Jul 23 2015
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls Jul 23 2015
Eli Lilly, Biogen Present Data at Alzheimer's Association - Analyst Blog Jul 23 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK